Rigel Pharmaceuticals (RIGL) Shares are Up 6.69%

Rigel Pharmaceuticals (RIGL) : Traders are bullish on Rigel Pharmaceuticals (RIGL) as it has outperformed the S&P 500 by a wide margin of 8.52% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.51%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.69% in the last 1 week, and is up 7.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 6.7% and the 50-Day Moving Average is 21.57%.The 200 Day SMA reached 38.75%


Rigel Pharmaceuticals (NASDAQ:RIGL): After opening at $3.57, the stock dipped to an intraday low of $3.52 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.7 and the buying power remained strong till the end. The stock closed at $3.67 for the day, a gain of 2.80% for the day session. The total traded volume was 795,820. The stocks close on the previous trading day was $3.67.

Rigel Pharmaceuticals (RIGL) : 4 investment research analysts covering Rigel Pharmaceuticals (RIGL) have an average price target of $8.25 for the near short term. The highest target price given by the Brokerage Firm to the stock is $11 and the lowest target is $6 for the short term. Analysts expect the variance to be within $2.22 of the average price.

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. It has various product candidates in development: fostamatinib; R348; two oncology product candidates, and two preclinical programs. Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor. R348 is a topical janus kinase (JAK)/SYK inhibitor. It is conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.